<?xml version="1.0" encoding="UTF-8"?>
<p id="p0300">Immune cells are responsible for the secretion of inflammatory factors. So, decreasing the lymphocyte count might result in CRS suppression. Rituximab, Etoposide, and Lenumab are Mabs used to reduce CD8
 <sup>+</sup> T cells, decrease the release of interferon-gamma, and to treat CRS and hemophagocytic lymphohistiocytosis (FHLH) 
 <xref rid="b0620" ref-type="bibr">[124]</xref>, 
 <xref rid="b0625" ref-type="bibr">[125]</xref>.
</p>
